Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...

Shares of Bristol Myers Squibb Co. slid 3.42% to $46.86 Friday, on what proved to be an all-around dismal trading session for ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of ...

The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo ...

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Discover 14 "safer" S&P 500 dividend stocks with strong free cash flow for stable payouts. Learn how they may offer 27%-53% ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

The primary exposure was a first-trimester prescription fill of nitrofurantoin, TMP-SMX, fluoroquinolones (ciprofloxacin, levofloxacin, ofloxacin), and β-lactams to treat UTI. Any congenital ...

JLL helped biopharma Kardigan establish its East Coast presence in Princeton, among several recent office sector deals.

Researchers sought to determine whether adding elotuzumab to PVd would be safe and effective in treating patients with relapsed or refractory MM.

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in ...